FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147718573> ?p ?o ?g. }

• W2147718573 endingPage "1192" @default.
• W2147718573 startingPage "1182" @default.
• W2147718573 abstract "The National Cancer Institute of Canada Clinical Trials Group CO.17 study showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor–targeting antibody, was given in addition to best supportive care. We conducted a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274). Direct medical resource utilization data were collected, including medications, physician visits, toxicity management, blood products, emergency department visits, and hospitalizations. Mean survival times for the study arms were calculated for the entire population and for the subset of patients with wild-type KRAS tumors over an 18- to 19-month period. All costs were presented in 2007 Canadian dollars. One-way and probabilistic sensitivity analysis was used to determine the robustness of the results. Cost-effectiveness acceptability curves were determined. The 95% confidence intervals (CIs) for the incremental cost-effectiveness ratios and the incremental cost–utility ratios were estimated by use of a nonparametric bootstrapping method (with 1000 iterations). For the entire study population, the mean improvement in overall and quality-adjusted survival with cetuximab was 0.12 years and 0.08 quality-adjusted life-years (QALYs), respectively. The incremental cost with cetuximab compared with best supportive care was $23 969. The incremental cost-effectiveness ratio was $199 742 per life-year gained (95% CI = $125 973 to $652 492 per life-year gained) and the incremental cost–utility ratio was $299 613 per QALY gained (95% CI = $187 440 to $898 201 per QALY gained). For patients with wild-type KRAS tumors, the incremental cost with cetuximab was $33 617 and mean gains in overall and quality-adjusted survival were 0.28 years and 0.18 QALYs, respectively. The incremental cost-effectiveness ratio was $120 061 per life-year gained (95% CI = $88 679 to $207 075 per life-year gained) and the incremental cost–utility ratio was $186 761 per QALY gained (95% CI = $130 326 to $334 940 per QALY gained). In a sensitivity analysis, cetuximab cost and patient survival were the only variables that influenced cost-effectiveness. The incremental cost-effectiveness ratio of cetuximab over best supportive care alone in unselected advanced colorectal cancer patients is high and sensitive to drug cost. Incremental cost-effectiveness ratios were lower when the analysis was limited to patients with wild-type KRAS tumors." @default.
• W2147718573 created "2016-06-24" @default.
• W2147718573 creator A5000275974 @default.
• W2147718573 creator A5001556202 @default.
• W2147718573 creator A5003643368 @default.
• W2147718573 creator A5008173055 @default.
• W2147718573 creator A5012549313 @default.
• W2147718573 creator A5013044281 @default.
• W2147718573 creator A5031200997 @default.
• W2147718573 creator A5031504642 @default.
• W2147718573 creator A5047478386 @default.
• W2147718573 creator A5050273828 @default.
• W2147718573 creator A5058526313 @default.
• W2147718573 creator A5063121757 @default.
• W2147718573 creator A5063860482 @default.
• W2147718573 creator A5074146787 @default.
• W2147718573 creator A5080423970 @default.
• W2147718573 creator A5080619433 @default.
• W2147718573 creator A5081680405 @default.
• W2147718573 date "2009-08-07" @default.
• W2147718573 modified "2023-10-18" @default.
• W2147718573 title "Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial" @default.
• W2147718573 cites W1974435973 @default.
• W2147718573 cites W1979044834 @default.
• W2147718573 cites W1995517770 @default.
• W2147718573 cites W1998551984 @default.
• W2147718573 cites W1999250974 @default.
• W2147718573 cites W2001611786 @default.
• W2147718573 cites W2003184958 @default.
• W2147718573 cites W2008070553 @default.
• W2147718573 cites W2016342976 @default.
• W2147718573 cites W2020274130 @default.
• W2147718573 cites W2032287810 @default.
• W2147718573 cites W2054613048 @default.
• W2147718573 cites W2057458801 @default.
• W2147718573 cites W2069703793 @default.
• W2147718573 cites W2072508272 @default.
• W2147718573 cites W2074530116 @default.
• W2147718573 cites W2095095509 @default.
• W2147718573 cites W2098223440 @default.
• W2147718573 cites W2100589633 @default.
• W2147718573 cites W2101814490 @default.
• W2147718573 cites W2106789440 @default.
• W2147718573 cites W2114719904 @default.
• W2147718573 cites W2120490763 @default.
• W2147718573 cites W2127847091 @default.
• W2147718573 cites W2142564546 @default.
• W2147718573 cites W2148199952 @default.
• W2147718573 cites W2155311724 @default.
• W2147718573 cites W2163295338 @default.
• W2147718573 cites W2164837623 @default.
• W2147718573 cites W2167539263 @default.
• W2147718573 cites W2250036631 @default.
• W2147718573 cites W2409420104 @default.
• W2147718573 cites W4385789423 @default.
• W2147718573 doi "https://doi.org/10.1093/jnci/djp232" @default.
• W2147718573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19666851" @default.
• W2147718573 hasPublicationYear "2009" @default.
• W2147718573 type Work @default.
• W2147718573 sameAs 2147718573 @default.
• W2147718573 citedByCount "125" @default.
• W2147718573 countsByYear W21477185732012 @default.
• W2147718573 countsByYear W21477185732013 @default.
• W2147718573 countsByYear W21477185732014 @default.
• W2147718573 countsByYear W21477185732015 @default.
• W2147718573 countsByYear W21477185732016 @default.
• W2147718573 countsByYear W21477185732017 @default.
• W2147718573 countsByYear W21477185732018 @default.
• W2147718573 countsByYear W21477185732019 @default.
• W2147718573 countsByYear W21477185732020 @default.
• W2147718573 countsByYear W21477185732021 @default.
• W2147718573 countsByYear W21477185732022 @default.
• W2147718573 countsByYear W21477185732023 @default.
• W2147718573 crossrefType "journal-article" @default.
• W2147718573 hasAuthorship W2147718573A5000275974 @default.
• W2147718573 hasAuthorship W2147718573A5001556202 @default.
• W2147718573 hasAuthorship W2147718573A5003643368 @default.
• W2147718573 hasAuthorship W2147718573A5008173055 @default.
• W2147718573 hasAuthorship W2147718573A5012549313 @default.
• W2147718573 hasAuthorship W2147718573A5013044281 @default.
• W2147718573 hasAuthorship W2147718573A5031200997 @default.
• W2147718573 hasAuthorship W2147718573A5031504642 @default.
• W2147718573 hasAuthorship W2147718573A5047478386 @default.
• W2147718573 hasAuthorship W2147718573A5050273828 @default.
• W2147718573 hasAuthorship W2147718573A5058526313 @default.
• W2147718573 hasAuthorship W2147718573A5063121757 @default.
• W2147718573 hasAuthorship W2147718573A5063860482 @default.
• W2147718573 hasAuthorship W2147718573A5074146787 @default.
• W2147718573 hasAuthorship W2147718573A5080423970 @default.
• W2147718573 hasAuthorship W2147718573A5080619433 @default.
• W2147718573 hasAuthorship W2147718573A5081680405 @default.
• W2147718573 hasConcept C112930515 @default.
• W2147718573 hasConcept C121608353 @default.
• W2147718573 hasConcept C126322002 @default.
• W2147718573 hasConcept C143998085 @default.
• W2147718573 hasConcept C159110408 @default.
• W2147718573 hasConcept C2779951463 @default.
• W2147718573 hasConcept C2779998722 @default.

• next